Cellular Differences in Asthma Identified in First Lung Mapping Project
For the first time, the interactions of lung-resident structural and inflammatory cells have been profiled in both healthy individuals and those with asthma.
All articles by Britt Gambino
How Can Technology Alleviate Burdens of Asthma and COPD?: A Q&A With Propeller Health CEO
David Van Sickle, CEO and cofounder of Propeller Health, offers his insight into how technology can improve outcomes in patients with asthma and COPD.
Bayer Grant Will Award Up to $1 Million in PAH, CTEPH Research
Pulmonary Hypertension Accelerated Bayer Awards, a new program launched by Bayer US, will award up to $1 million in grants to support clinical research in pulmonary hypertension.
Asthma Awareness Month: A Q&A With David A. Hill, MD, of the American Lung Association
In honor of Asthma Awareness Month, Pulmonology Advisor interviewed David A. Hill, MD, of the American Lung Association, to highlight the advances in care as well as gaps in knowledge and treatment.
Decreasing Ventilator-Associated Pneumonia in Level I Trauma Patients
Performing therapeutic bronchoscopy at the time of intensive care unit admission may decrease ventilator-associated pneumonia incidence in patients with level I trauma.
TB Treatment Monitoring: Molecular Bacterial Load Assay vs Standard Testing
Compared with standard of care tests and most clinical signs, the molecular bacterial load assay demonstrated higher sensitivity and more rapid turnaround times for monitoring tuberculosis treatment.
Improvements in PAH When Transitioned From PDEi to Riociguat
Patients with pulmonary arterial hypertension experienced a significant improvement in World Health Organization Functional Class when transitioned from a phosphodiesterase type 5 inhibitor to riociguat.
FDA Approves Device to Make More Lungs Available for Transplant
The Xvivo Perfusion System can temporarily ventilate, oxygenate, and pump preservation solution through lungs previously deemed unacceptable for transplant.
Many Pediatric Asthma Cases Attributable to Nitrogen Dioxide Exposure
An estimated 4 million new pediatric asthma cases per year, or 13% of global incidence, may be attributable to ambient nitrogen dioxide exposure.
Cardiac Remodeling Biomarker May Identify High Risk Patients With PAH
Suppressor of tumorigenicity 2 may function as a biomarker to identify patients with pulmonary arterial hypertension with higher REVEAL risk scores.
Next post in Pulmonary Hypertension
